Loading...
•
Mar 31, 2020
Axsome Q1 2020 Earnings Report
Axsome reported financial results for Q1 2020 and provided a business update.
Key Takeaways
Axsome Therapeutics reported clinical successes in its late-stage pipeline, including positive efficacy data in depression, Alzheimer’s disease agitation, migraine, narcolepsy, and fibromyalgia. Two NDA submissions, for AXS-05 in MDD and AXS-07 in migraine, are on track for 4Q 2020. The company's cash at March 31, 2020 is expected to fund operations for at least two years.
Positive pivotal Phase 2/3 results for AXS-05 in Alzheimer’s disease agitation further deepen innovative pipeline
Positive efficacy results in 5 significant CNS indications with 4 candidates advance broad late-stage pipeline
Two NDA submissions, for AXS-05 in MDD and AXS-07 in migraine, on track for 4Q 2020
Pre-commercialization activities underway for potentially first-in-class or best-in-class CNS therapies
Forward Guidance
Axsome believes that its cash at March 31, 2020 will be sufficient to fund the company’s anticipated operations, based on its current operating plans, for at least two years.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...